Alyeska Investment Group, L.P. In8 Bio, Inc. Call Options Transaction History

Alyeska Investment Group, L.P.

  • $25.4 Billion
  • Q2 2025

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.69 - $2.34 $565,573 - $1.92 Million
819,672 New
819,672 $1.13 Million

Others Institutions Holding INAB

# of Institutions
3
Shares Held
344K
Call Options Held
0
Put Options Held
0
View Full List

About IN8BIO, INC.

INAB Quotes by TradingView
  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $51.5M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email